Veru (NASDAQ:VERU - Get Free Report) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect Veru to post earnings of ($0.06) per share for the quarter.
Veru (NASDAQ:VERU - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.01. Veru had a negative return on equity of 112.75% and a negative net margin of 223.85%. On average, analysts expect Veru to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Veru Price Performance
Shares of NASDAQ VERU traded up $0.00 during trading on Wednesday, hitting $0.51. 260,893 shares of the company were exchanged, compared to its average volume of 1,757,158. The company has a market cap of $74.07 million, a price-to-earnings ratio of -1.95 and a beta of -0.74. Veru has a 1 year low of $0.45 and a 1 year high of $1.70. The firm's fifty day moving average price is $0.53 and its 200 day moving average price is $0.64.
Insider Buying and Selling at Veru
In other news, Director Michael L. Rankowitz bought 95,279 shares of the stock in a transaction on Tuesday, February 18th. The shares were bought at an average price of $0.55 per share, with a total value of $52,403.45. Following the completion of the acquisition, the director now owns 195,279 shares of the company's stock, valued at approximately $107,403.45. This trade represents a 95.28 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 14.90% of the stock is currently owned by corporate insiders.
Veru Company Profile
(
Get Free Report)
Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.
Featured Articles
Before you consider Veru, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veru wasn't on the list.
While Veru currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
